Elanco Animal Health Incorporated (ELAN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
24/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseELAN / S&P 2.84% / 15.20% |
LoseELAN / S&P 11.95% / 15.00% |
LoseELAN / S&P -147.67% / 50.40% |
| 2026-Q11/3 |
WinELAN / S&P 5.74% / -4.33% |
LoseELAN / S&P 10.53% / 11.30% |
LoseELAN / S&P -167.57% / 27.70% |
| 2025-Q41/3 |
WinELAN / S&P 12.36% / 2.65% |
LoseELAN / S&P 6.22% / 9.00% |
LoseELAN / S&P -171.64% / 13.40% |
| 2025-Q31/3 |
WinELAN / S&P 41.04% / 8.12% |
LoseELAN / S&P 3.08% / 4.61% |
LoseELAN / S&P -85.00% / 13.45% |
| 2025-Q21/3 |
WinELAN / S&P 36.00% / 10.94% |
LoseELAN / S&P -0.18% / 4.83% |
LoseELAN / S&P -133.73% / 10.63% |
| 2025-Q10/3 |
LoseELAN / S&P -13.29% / -4.27% |
LoseELAN / S&P 1.42% / 4.98% |
LoseELAN / S&P -127.92% / 10.57% |
| 2024-Q40/3 |
LoseELAN / S&P -17.56% / 2.41% |
LoseELAN / S&P 0.50% / 5.25% |
LoseELAN / S&P -126.80% / 6.15% |
| 2024-Q30/3 |
LoseELAN / S&P 1.80% / 5.89% |
LoseELAN / S&P 1.99% / 5.89% |
LoseELAN / S&P -117.24% / 6.11% |
| 2024-Q21/3 |
LoseELAN / S&P -11.36% / 4.28% |
LoseELAN / S&P 3.86% / 5.38% |
WinELAN / S&P 1008.70% / 5.12% |
| 2024-Q11/3 |
LoseELAN / S&P 9.26% / 10.56% |
LoseELAN / S&P -1.76% / 5.71% |
WinELAN / S&P 5200.00% / 5.59% |
| 2023-Q42/3 |
WinELAN / S&P 32.56% / 11.69% |
LoseELAN / S&P 0.11% / 6.81% |
WinELAN / S&P 1462.50% / 7.78% |
| 2023-Q32/3 |
WinELAN / S&P 11.73% / -3.27% |
LoseELAN / S&P -3.79% / 7.52% |
WinELAN / S&P 759.26% / -5.03% |
| 2023-Q20/3 |
LoseELAN / S&P 7.02% / 8.74% |
LoseELAN / S&P -6.87% / 9.50% |
LoseELAN / S&P -34.29% / -8.57% |
| 2023-Q10/3 |
LoseELAN / S&P -23.08% / 7.50% |
LoseELAN / S&P -6.42% / 10.77% |
LoseELAN / S&P -93.42% / -15.69% |
| 2022-Q40/3 |
LoseELAN / S&P -1.53% / 7.56% |
LoseELAN / S&P -7.39% / 11.88% |
LoseELAN / S&P -83.67% / -17.99% |
| 2022-Q30/3 |
LoseELAN / S&P -36.78% / -4.88% |
LoseELAN / S&P -5.26% / 13.47% |
LoseELAN / S&P -82.00% / -1.41% |
| 2022-Q20/3 |
LoseELAN / S&P -24.76% / -16.10% |
LoseELAN / S&P 2.07% / 13.71% |
LoseELAN / S&P -77.85% / 11.04% |
| 2022-Q11/3 |
LoseELAN / S&P -8.07% / -4.60% |
WinELAN / S&P 23.10% / 15.97% |
LoseELAN / S&P -40.62% / 42.23% |
| 2021-Q41/3 |
LoseELAN / S&P -11.01% / 11.03% |
WinELAN / S&P 45.55% / 15.00% |
LoseELAN / S&P -23.44% / 96.40% |
| 2021-Q32/3 |
LoseELAN / S&P -8.07% / 0.58% |
WinELAN / S&P 64.02% / 10.77% |
WinELAN / S&P 163.16% / 69.42% |
| 2021-Q23/3 |
WinELAN / S&P 17.79% / 8.55% |
WinELAN / S&P 62.37% / 6.58% |
WinELAN / S&P 532.00% / 51.81% |
| 2021-Q12/3 |
LoseELAN / S&P -3.98% / 6.17% |
WinELAN / S&P 28.66% / -1.06% |
WinELAN / S&P 6300.00% / 7.39% |
| 2020-Q41/3 |
LoseELAN / S&P 9.81% / 12.15% |
WinELAN / S&P 6.58% / -3.72% |
LoseELAN / S&P -773.68% / -33.42% |
| 2020-Q31/3 |
WinELAN / S&P 30.21% / 8.93% |
LoseELAN / S&P -5.26% / -2.04% |
LoseELAN / S&P -319.23% / -27.10% |
| 2020-Q20/3 |
LoseELAN / S&P -4.20% / 20.54% |
LoseELAN / S&P -8.81% / -0.46% |
LoseELAN / S&P -158.14% / -27.11% |
| 2020-Q10/3 |
LoseELAN / S&P -23.97% / -19.60% |
LoseELAN / S&P -2.08% / 3.47% |
LoseELAN / S&P -116.67% / -14.75% |
| 2019-Q41/3 |
WinELAN / S&P 10.76% / 9.07% |
LoseELAN / S&P 0.14% / 5.36% |
LoseELAN / S&P -32.14% / 2.99% |
| 2019-Q30/3 |
LoseELAN / S&P -21.33% / 1.70% |
LoseELAN / S&P 2.04% / 5.02% |
LoseELAN / S&P ELAN unavailable / 0.21% |
| 2019-Q21/3 |
WinELAN / S&P 5.39% / 4.30% |
LoseELAN / S&P 3.90% / 6.64% |
LoseELAN / S&P ELAN unavailable / 8.65% |
| 2019-Q10/3 |
LoseELAN / S&P 1.71% / 13.65% |
LoseELAN / S&P ELAN unavailable / 8.12% |
LoseELAN / S&P ELAN unavailable / 14.29% |
| 2018-Q41/3 |
WinELAN / S&P -9.63% / -13.52% |
LoseELAN / S&P ELAN unavailable / 9.05% |
LoseELAN / S&P ELAN unavailable / 18.23% |
| 2018-Q30/3 |
LoseELAN / S&P ELAN unavailable / 7.71% |
LoseELAN / S&P ELAN unavailable / 10.21% |
LoseELAN / S&P ELAN unavailable / 19.06% |
| 2018-Q20/3 |
LoseELAN / S&P ELAN unavailable / 3.43% |
LoseELAN / S&P ELAN unavailable / 9.03% |
LoseELAN / S&P ELAN unavailable / 14.46% |
| 2018-Q10/3 |
LoseELAN / S&P ELAN unavailable / -0.76% |
LoseELAN / S&P ELAN unavailable / 7.68% |
LoseELAN / S&P ELAN unavailable / 12.46% |
| 2017-Q40/3 |
LoseELAN / S&P ELAN unavailable / 6.64% |
LoseELAN / S&P ELAN unavailable / 7.03% |
LoseELAN / S&P ELAN unavailable / 13.82% |
| 2017-Q30/3 |
LoseELAN / S&P ELAN unavailable / 4.48% |
LoseELAN / S&P ELAN unavailable / 5.68% |
LoseELAN / S&P ELAN unavailable / 17.57% |
| 2017-Q20/3 |
LoseELAN / S&P ELAN unavailable / 3.09% |
LoseELAN / S&P ELAN unavailable / 4.83% |
LoseELAN / S&P ELAN unavailable / 17.74% |
| 2017-Q10/3 |
LoseELAN / S&P ELAN unavailable / 6.07% |
LoseELAN / S&P ELAN unavailable / 3.67% |
LoseELAN / S&P ELAN unavailable / 13.32% |
| 2016-Q40/3 |
LoseELAN / S&P ELAN unavailable / 3.82% |
LoseELAN / S&P ELAN unavailable / 2.09% |
LoseELAN / S&P ELAN unavailable / 7.05% |
| 2016-Q30/3 |
LoseELAN / S&P ELAN unavailable / 3.85% |
LoseELAN / S&P ELAN unavailable / 0.20% |
LoseELAN / S&P ELAN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ELAN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 33.46% | 20.78% |
| Annualized return | 33.46% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ELAN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -26.96% | 83.14% |
| Annualized return | -6.09% | 12.86% |
10Y · 2018-09-20 to 2026-08-27
| Metric | ELAN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -31.97% | 319.30% |
| Annualized return | -3.78% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |